Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer

Radiation Oncology

Table 4 Relationship between disease-free survival with clinico-pathological factors

Variable N= 112	1-year DFS (months ± SD)	2-year DFS (months ± SD)	5-year DFS (months ± SD)	Univariate analysis p	Multivariate analysis HR (95% CI) p
Age (years)				0.09
>50	92 ± 3	82 ± 5	82 ± 5
<50	96 ± 2	94 ± 2	92 ± 3
Clinical T stage*				0.05
T2	90 ± 6	86 ± 7	86 ± 7
T3	98 ± 2	96 ± 2	96 ± 2
T4	87 ± 5	82 ± 6	78 ± 6
Clinical N stage*				0.79
N1	92 ± 3	90 ± 4	90 ± 4
N2/N3	92 ± 3	87 ± 4	84 ± 5
Clinical stage*				0.03	3.1 (1.02–9.74,) 0.0406
IIB/IIIA	95 ± 2	93 ± 3	93 ± 3
IIIB	87 ± 5	82 ± 6	78 ± 6
Estrogen receptors				0.012	0.3 (0.91–1.22,) 0.97
Negative	92 ± 3	85 ± 4	83 ± 4
Positive	97 ± 2	93 ± 3	93 ± 3
Histological grade†				0.04	3.5 (0.79–16.28,) 0.98
Low/moderate	100	97 ± 2	94 ± 3
High	91 ± 3	83 ± 4	83 ± 4
Pathological response				0.56
pCR/microscopic	92 ± 3	88 ± 3	86 ± 4
Residual	94 ± 4	91 ± 4	91 ± 4

Abbreviations: DFS = disease-free survival; SD = standard deviation; HR = Hazard ratio; 95% CI = 95% confidence interval.
* 6th edition of the American Joint Committee on Cancer TNM classification and staging system.
† Scarff-Bloom-Richardson (SBR) scale.

ISSN: 1748-717X